FRED HUTCHINSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: https://www.fredhutch.org

Clinical Trials

Cellular Adoptive Immunotherapy in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer

Phase 1

Completed

Conditions: Ovarian Cancer
Peritoneal Cavity Cancer

First Posted Date: 2005-01-10

Last Posted Date: 2010-05-07

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 18

Registration Number: NCT00101257

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Long-Term Effects of Iodine I Tositumomab and Autologous Bone Marrow or Stem Cell Transplantation in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Completed

Conditions: Quality of Life
Lymphoma

First Posted Date: 2004-12-08

Last Posted Date: 2015-10-14

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 36

Registration Number: NCT00098566

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant

Phase 2

Completed

Conditions: Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Chronic Lymphocytic Leukemia
Myelodysplastic/Myeloproliferative Neoplasm
Plasma Cell Myeloma
Waldenstrom Macroglobulinemia
Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Graft Versus Host Disease
Non-Hodgkin Lymphoma
Hodgkin Lymphoma

Interventions: Drug: Cyclosporine
Drug: Mycophenolate Mofetil
Drug: Pentostatin
Biological: Therapeutic Allogeneic Lymphocytes

First Posted Date: 2004-11-09

Last Posted Date: 2020-01-31

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 36

Registration Number: NCT00096161

Locations: 🇺🇸
LDS Hospital, Salt Lake City, Utah, United States
🇺🇸
VA Puget Sound Health Care System, Seattle, Washington, United States
🇮🇹
University of Torino, Torino, Italy

and more 2 locations

Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation

Phase 2

Completed

Conditions: Chronic Myeloproliferative Disorders
Graft Versus Host Disease
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Diseases

First Posted Date: 2004-11-09

Last Posted Date: 2010-05-13

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT00096096

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Arsenic Trioxide and Etanercept in Treating Patients With Myelodysplastic Syndromes

Phase 1

Completed

Conditions: Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Diseases
Leukemia

First Posted Date: 2004-10-08

Last Posted Date: 2011-11-30

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 32

Registration Number: NCT00093366

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia

Phase 1

Completed

Conditions: Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Fanconi Anemia
Adult Acute Myeloid Leukemia in Remission
Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Childhood Acute Myeloid Leukemia in Remission
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Childhood Myelodysplastic Syndromes

Interventions: Drug: fludarabine phosphate
Drug: cyclosporine
Radiation: total-body irradiation
Procedure: allogeneic bone marrow transplantation
Procedure: allogeneic hematopoietic stem cell transplantation
Procedure: peripheral blood stem cell transplantation
Drug: mycophenolate mofetil

First Posted Date: 2004-10-08

Last Posted Date: 2017-02-20

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 2

Registration Number: NCT00093743

Locations: 🇺🇸
Riley Hospital for Children, Indianapolis, Indiana, United States
🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

and more 2 locations

Prevention of Graft-Versus-Host Disease in Patients With Hematologic Malignancies Who Are Receiving a Bone Marrow Transplant

Phase 1

Withdrawn

Conditions: Graft Versus Host Disease
Leukemia
Myelodysplastic Syndromes

First Posted Date: 2004-09-02

Last Posted Date: 2015-03-06

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT00002790

Monoclonal Antibody Followed by Bone Marrow Transplantation in Treating Patients With Acute Myelogenous Leukemia in Remission or First Relapse

Phase 2

Completed

Conditions: Leukemia

First Posted Date: 2004-08-31

Last Posted Date: 2010-03-30

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 30

Registration Number: NCT00002554

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia

Phase 2

Completed

Conditions: Leukemia

First Posted Date: 2004-08-23

Last Posted Date: 2010-04-02

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 30

Registration Number: NCT00002674

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer

Phase 2

Completed

Conditions: Accelerated Phase Chronic Myelogenous Leukemia
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Lymphoblastic Leukemia in Remission
Adult Acute Myeloid Leukemia in Remission
Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Adult Nasal Type Extranodal NK/T-cell Lymphoma

Interventions: Drug: fludarabine phosphate
Radiation: total-body irradiation
Drug: mycophenolate mofetil
Drug: tacrolimus
Other: laboratory biomarker analysis
Procedure: peripheral blood stem cell transplantation
Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation

First Posted Date: 2004-08-05

Last Posted Date: 2020-01-29

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 150

Registration Number: NCT00089011

Locations: 🇺🇸
VA Puget Sound Health Care System, Seattle, Washington, United States
🇺🇸
LDS Hospital, Salt Lake City, Utah, United States
🇺🇸
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States

and more 2 locations

Home Terms & Conditions Privacy Policy